What's in Nielsen BioSciences, Inc.'s pipeline?

Nielsen BioSciences, Inc. has 3 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Nielsen BioSciences, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nielsen-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Nielsen BioSciences, Inc. — Portfolio Competitive Intelligence Brief

Nielsen BioSciences, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Candida albicans Skin Test Antigen	Candida albicans Skin Test Antigen	marketed
Spherule-derived coccidioidin	Spherule-derived coccidioidin	phase 3			Infectious Disease
Candin, Intradermal Solution	Candin, Intradermal Solution	phase 3	Immunotherapeutic antigen preparation	Candida albicans antigens	Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Nielsen BioSciences, Inc.:

Cite this brief

Drug Landscape (2026). Nielsen BioSciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nielsen-biosciences-inc. Accessed 2026-05-16.